CAREERS
You will be associated with the research projects of the laboratory and will be notably in charge of: the culture of human or murine cell lines and their treatment with various pharmacological compounds, performing RT-PCR using RNA from murine or human tissues, and cells in culture, the analysis of the product of these RT-PCRs by…
Read MoreNEWS & EVENTS
Biocortech and Drug Safety Executive Council announce Technology Evaluation Consortium to validate novel toxicogenomic screening assay to predict potential drug-induced psychiatric adverse events Announcement Paris Biopark, Paris, France and Drug Safety Executive Council (DSEC), Needham, Massachusetts, United States- June 17, 2010 – Biocortech, the biopharmaceutical company dedicated to the development of drug safety screening assays and…
Read MoreCUSTOMERS & PARTNERS
Biocortech is very much partner-oriented and relationships with our customers and partners are key to the development of Biocortech’s technology and services. Over years, Biocortech build a network of academic collaborations and industry agreements that cover the different areas of research and development, such as neuronal plasticity. Biocortech acquired a deep understanding of the needs…
Read MorePRODUCTS & SERVICES
DIADEP Diagnostic and/or predictive biological test of depression and/or of depression severity (i.e., risk of suicidal behavior) First clinical trial started early 2009. This pilot trial aims at achieving a proof of concept of the test among a sub-population of patients EDITOX Drug screening assay of predictive neuropsychiatric toxicology of new chemical entities EDITOX® is…
Read More
SCIENCE & TECHNOLOGY
Receptor editing – which was initially described in immunology – is a regulation mechanism of key receptors (e.g. 5HT2cR, AMPAR) involved in brain diseases (such as depression, schizophrenia or neurodegenerative diseases) or in the mechanism of action of pharmacological agents (such as an antidepressant or anti-obesity drugs). Biocortech has developed the only technology enabling a…
Read MoreBOARD OF DIRECTORS
Dinah Weissmann Chairman of the Board, Chief Executive Director Jean François Pujol Director, Chief Scientific Director Jean Paul Leon Director Previously CFO and Executive VP Corporate Strategy of Sanofi. Jean-Paul is an expert of the big pharma environment. As a previous member of Sanofi top management, he was a strong contributor for more 25 years…
Read MoreManagement Team
Dinah Weissmann has served as Biocortech Chief Executive Officer since the founding of the company in 2001. Dr Weissmann is an expert in neurobiology, with 20 years’ experience in R&D; management. Prior to founding Biocortech, Dinah was a Senior Scientist at Roussel Uclaf (now Sanofi-Aventis). Her research background includes an appointment as a Research Director at…
Read MoreBusiness strategy
Diagnostics Biocortech is completing clinical proof of concept of its in vitro diagnostics tests for disease management of brain disorders and is interested in collaborating on their regulatory development, industrialization, marketing and commercialization, with industry partner(s) having a franchise in in vitro diagnostic market. Biocortech contemplates possibilities to develop and commercialize diagnostic tests for niche…
Read MoreHome
Biocortech is focusing on developing diagnostic application of receptor editing, an emerging field of rapidly growing interest that the company pioneered for the last years. Biocortech is now addressing the emerging market of biological testing of neuropsychiatric diseases and aiming at being an early entrant in the market of biological testing of depression, with a proprietary…
Read More